Project Grant R01AG093773
Award Date
7/1/25
Completion Date
6/30/30
Dollars Obligated
$1.3M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute on Aging
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will provide $3,317,325 to the University of California, Irvine and collaborative institutions to investigate the role of immune deregulation and nerve growth factor (NGF) dysmetabolism in the development of Alzheimer's disease in individuals with Down syndrome. The primary goals are to elucidate the relationships between immune and NGF alterations with Alzheimer's disease...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
This $3.386 million project grant from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will fund research at Beth Israel Deaconess Medical Center to develop a potential treatment for Down syndrome. The grantee will assess the efficiency of using a modified CRISPR approach and single nucleotide polymorphism-based guide RNA targeting to silence one of three copies of human chromosome 21 in the Tc1 mouse model of Down syndrome. If successful, this research could...
The Trustees of the University of Pennsylvania received a $3.7 million Project Grant award from the Department of Health and Human Services National Institutes of Health Office of the Director to address co-occurring conditions in individuals with Down syndrome. Funded under the Trans-NIH Research Support program (CFDA 93.310), the three-year project will test whether reducing proteostatic stress with the FDA-approved small molecule 4-phenylbutyrate can ameliorate sleep deficits, metabolic...
This Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the cellular and synaptic mechanisms underlying cognitive disabilities in Down syndrome. The award to the University of Colorado-Denver will utilize a novel combination of two-photon microscopy, electrophysiology, chemogenetics, and pharmacological...
The University of California, San Diego (UCSD) was awarded a $1,698,323 Project Grant from the National Institute on Aging (CFDA 93.866 Aging Research) to develop and validate a mouse model for Alzheimer's disease in Down syndrome (DS-AD). The goal is to create a genetically modified mouse that replicates key pathological features of DS-AD, including amyloid plaques, congophilic angiopathy, and neurofibrillary tangles. In the initial R61 phase, the researchers will demonstrate feasibility,...
The National Institutes of Health Trans-NIH Research Support program awarded a $4,010,262 Project Grant to the University of Illinois to study the role of amyloid precursor protein in neurogenesis and Alzheimer's disease pathology in Down syndrome. The three-year grant will support research examining how overexpression of amyloid precursor protein, which is located on chromosome 21 and thus triplicated in Down syndrome, impacts neural stem cell proliferation, neuronal differentiation, and...
The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
This $3.44 million project grant from the Department of Health and Human Services National Institutes of Health Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), will fund research at the University of Massachusetts Medical School to suppress aneuploidy-associated phenotypes in Down syndrome. Specifically, the researchers will identify the mechanisms by which an extra copy of chromosome 21 affects nuclear structure and function in cells, investigate how...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Trustees of Columbia University in the City of New York provides $452,375 to investigate the potential use of the APLP1 protein as an early biomarker for Alzheimer's disease in individuals with Down syndrome. The project aims to leverage recent findings linking endosomal trafficking defects to the early pathology of Alzheimer's disease, which is observed decades before classical...